Back to results
US 12,583,934 B2Granted
Anti-CD26 antibodies and uses thereof
AssigneeAdienne S.A.
InventorAntonio Francesco Di Naro
Life of this patent
Estimating the term…
Abstract
The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.
Claims18
An isolated nucleic acid molecule comprising:
- (a) a nucleotide sequence encoding an antibody that specifically binds human CD26, the antibody comprising a heavy chain variable region and a light chain variable region, wherein:
- i) the heavy chain variable region comprises a VH CDR1 comprising the sequence of SEQ ID NO:
- 133, a VH CDR2 comprising the sequence of SEQ ID NO:
- 134, and a VH CDR3 comprising the sequence of SEQ ID NO:
- 1;
- and
- ii) the light chain variable region comprises a VL CDR1 comprising the sequence of SEQ ID NO:
- 129 or 131, a VL CDR2 comprising the sequence of SEQ ID NO:
- 130 or 132, and a VL CDR3 comprising the sequence of SEQ ID NO:
- 2 or 3;
- or
- (b) a nucleotide sequence complementary to (a).
9 more elements
An isolated nucleic acid molecule comprising:
- (a) a nucleotide sequence encoding an antibody that specifically binds human CD26, wherein the antibody is capable of binding a CD26 epitope comprising the amino acids Asp329, Asn338, Leu340, Val341, Ala342, Arg343, Asp367, Asn369, Tyr386, Gln388, Ile389, Asp390, Lys391, Lys392, Asp393, Thr395, Ser412, Leu436, Ser437, Asp438 and Tyr439 of SEQ ID NO:
- 144, wherein the antibody comprises a VH CDR1 comprising the sequence of SEQ ID NO:
- 133, a VH CDR2 comprising the sequence of SEQ ID NO:
- 134, and a VH CDR3 comprising the sequence of SEQ ID NO:
- 1;
- and the light chain variable region comprises a VL CDR1 comprising the sequence of SEQ ID NO:
- 129, a VL CDR2 comprising the sequence of SEQ ID NO:
- 130, and a VL CDR3 comprising the sequence of SEQ ID NO:
- 2;
- or
- (b) a nucleotide sequence complementary to (a).
8 more elements
Dependencies are inferred from the claim text.